Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPLIFY: Acalabrutinib + Venetoclax ± Obinutuzumab vs Chemoimmunotherapy in First-line CLL Without del(17p) or TP53 Mutation
2023-509349-11-00Phase 3Authorised
- Sponsor
- Acerta Pharma
- Start
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib, venetoclax and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by Acerta Pharma. Primary endpoint: Progression-free survival (PFS) by IRC. Planned start Jul 2024; status: authorised.
02
Drugs
acalabrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-509349-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509349-11-00.